News in brief

AddLife: Deal means further expansion outside Nordic region


AddLife is to acquire all shares in part of Biolin Scientific AB which has been owned by Ratos since 2010.

The firm said it means further expansion outside the Nordic region and the deal will have a marginally positive effect on earnings per share.

Biolin Scientific AB sells to universities and industry with a turnover around SEK 100m (€10.3m).

Operations are in two independent subsidiaries called Analytical Instruments and Drug Discovery.

With the divestment of Analytical Instruments, Drug Discovery will be run as an independent company in Ratos as Sophion.

"We have chosen to divest Analytical Instruments to AddLife, which will become a new, long-term owner with similar operations in Life Science. At the same time, this will enable increased focus on Sophion's core operations as an independent company," said Christina Rubenhag, CEO of Biolin Scientific Holding.

The Nordic developer and producer of analytical instruments for material analysis at the nanoscale will be part of the Labtech business area within AddLife and marks the fourth acquisition since March this year.

Addlife said customers within life science market are primarily research, university and academia and pharmaceutical and food industry including AstraZeneca, Eurofins and Novo Nordisk.

The technique is based on research at Chalmers University of Technology in measurement technology at the nanoscale.

Biolin Scientific AB has global sales through subsidiaries in US, UK and China and distributors.

Headquartered in Sweden it has research and production in Sweden and Finland with 61 employees.

Peter Simonsbacka, business area manager Labtech at AddLife, said material analysis at the nanoscale is an area where global developments emerge rapidly. 

As a world leading supplier of instruments for studies of material characteristics at the nanoscale Biolin Scientific contribute to creating new innovative products and solutions in a variety of areas for their customers.

Related News


Life Sciences a ‘blueprint’ for future food standards - Deloitte

Allergenic ingredients were not correctly labelled on 10% of products. ©iStock/piotr_malczyk

One in 10 allergenic ingredients not correctly labelled – study

Image: iStock/sumos

Danaher set to buy purification consumables firm Phenomenex

The transaction is expected to close by the end of Q2 2016

Affymetrix acquisition strengthens biosciences – Thermo Fisher

The deal is expected to be completed by early 2017

Thermo: FEI deal will complement mass spec portfolio

Olga Padilla-Zakour, Kathryn Boor, state Senator Michael Nozzolio, Susan Brown and Betsy Bihn. Picture: Patrick Cameron

State funding helps Cornell expand food safety capacity

Merck: “We will give VWR access to more Merck Millipore products..."

Merck signs food analytics deal in western Europe

Agilent Technologies to separate into two public companies. Picture: The firm's Santa Clara Headquarters

Agilent splits in two, remains focussed on food

Related Products

See more related products

Submit a comment

Your comment has been saved

Post a comment

Please note that any information that you supply is protected by our Privacy and Cookie Policy. Access to all documents and request for further information are available to all users at no costs, In order to provide you with this free service, William Reed Business Media SAS does share your information with companies that have content on this site. When you access a document or request further information from this site, your information maybe shared with the owners of that document or information.